Design of multi-epitope vaccine candidate against SARS-CoV-2: a<i>in-silico</i>study
K. Abraham Peele, T. Srihansa, S. Krupanidhi, Vijaya Sai Ayyagari, T. C. Venkateswarulu
Abstract
composed of 425 amino acids including the 50S ribosomal protein adjuvant and the construct was computationally validated in terms of antigenicity, allergenicity and stability on considering all critical parameters into consideration. The results subjected to the modeling and docking studies of vaccine were validated. Molecular docking study revealed the protein-protein binding interactions between the vaccine construct and TLR-3 immune receptor. The MD simulations confirmed stability of the binding pose. The immune simulation results showed significant response for immune cells. The findings of the study confirmed that the final vaccine construct of chimeric peptide could able to enhance the immune response against nCoV-19.